We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel 3D Growth Chamber Designed for Investigating Effects of Electric Fields on Cancer

By LabMedica International staff writers
Posted on 19 Jul 2016
A team of bioengineers designed and manufactured a novel microfluidic device for use in studying the effects of an electric field on the growth and spread of cancer cells.

A promising alternative approach to cancer therapy is based on exposing the tumor to an alternating electric field. More...
The current study describes a device designed to facilitate research for understanding the mechanisms involved in the disruption of the cancer cell cycle by the electric field as well as any potential adverse effects on non-cancerous cells.

Investigators at The Singapore-MIT Alliance for Research and Technology (SMART) (Singapore) engineered a microfluidic device with embedded contactless electrodes to culture cells in the presence of an alternating electric field in a highly controlled microenvironment.

The device was fabricated from PDMS (polydimethylsiloxane), and a pattern of small channels was inscribed across its surface. A conductive mixture was prepared from micron-sized silver flakes and PDMS, and the mixture was injected into separate channels in the device to form two separate electrodes. In the region between the electrodes, it was possible to inject hydrogels - which created a three-dimensional microenvironment - containing healthy human endothelial cells or breast or lung cancer cells as well as small tumor masses. Cells growing in the three-dimensional matrix were exposed to alternating electric fields at frequencies of 150 or 200 kilohertz, continuously, at an intensity of 1.1 volts per centimeter.

To demonstrate the potential of the system for aiding in the design and testing of new therapeutic approaches, cancer cells and cancer cell aggregates were cultured individually in the device or were co-cultured with endothelial cells.

Results published in the May 24, 2016, online edition of the journal Scientific Reports revealed that the metastatic potential of the cancer cells was reduced after electric field treatment. Moreover, the proliferation rate of the treated cancer cells was lower compared with that of untreated cells, while the morphologies and proliferative capacities of the endothelial cells were not significantly affected.

“We hope this device will increase interest by researchers who are exploring the effect of electric fields on different types of cancer,” said contributing author Dr. Giulia Adriani, a research scientist at SMART. “In our study, we noticed the effect was limited to the cancer cell at the tested frequencies and intensities, but we really need to explore other cells and parameters. For personalized medicine, you can test if a recipe works for a specific person. In three days, you can have an answer. And for many cancer patients who are dying of metastasis, time is everything.”

Related Links:
Singapore-MIT Alliance for Research and Technology



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.